<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-03T21:21:08Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/107692" metadataPrefix="qdc">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/107692</identifier><datestamp>2025-03-18T14:09:08Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>2D/3D-QSAR Model Development Based on a Quinoline Pharmacophoric Core for the Inhibition of Plasmodium falciparum: An In Silico Approach with Experimental Validation</dc:title>
   <dc:creator>Lorca, Marcos</dc:creator>
   <dc:creator>Muscia, Gisela C.</dc:creator>
   <dc:creator>Pérez Benavente, Susana</dc:creator>
   <dc:creator>Bautista Santa Cruz, José Manuel</dc:creator>
   <dc:creator>Acosta, Alison</dc:creator>
   <dc:creator>González, César</dc:creator>
   <dc:creator>Sabadini, Gianfranco</dc:creator>
   <dc:creator>Mella, Jaime</dc:creator>
   <dc:creator>Asís, Silvia E.</dc:creator>
   <dc:creator>Mellado, Marco</dc:creator>
   <dcterms:abstract>Malaria is an infectious disease caused by Plasmodium spp. parasites, with widespread drug resistance to most antimalarial drugs. We report the development of two 3D-QSAR models based on comparative molecular field analysis (CoMFA), comparative molecular similarity index analysis (CoMSIA), and a 2D-QSAR model, using a database of 349 compounds with activity against the P. falciparum 3D7 strain. The models were validated internally and externally, complying with all metrics (q2 > 0.5, r2test > 0.6, r2m > 0.5, etc.). The final models have shown the following statistical values: r2test CoMFA = 0.878, r2test CoMSIA = 0.876, and r2test 2D-QSAR = 0.845. The models were experimentally tested through the synthesis and biological evaluation of ten quinoline derivatives against P. falciparum 3D7. The CoMSIA and 2D-QSAR models outperformed CoMFA in terms of better predictive capacity (MAE = 0.7006, 0.4849, and 1.2803, respectively). The physicochemical and pharmacokinetic properties of three selected quinoline derivatives were similar to chloroquine. Finally, the compounds showed low cytotoxicity (IC50 > 100 µM) on human HepG2 cells. These results suggest that the QSAR models accurately predict the toxicological profile, correlating well with experimental in vivo data.</dcterms:abstract>
   <dcterms:dateAccepted>2024-08-27T07:18:06Z</dcterms:dateAccepted>
   <dcterms:available>2024-08-27T07:18:06Z</dcterms:available>
   <dcterms:created>2024-08-27T07:18:06Z</dcterms:created>
   <dcterms:issued>2024-07-04</dcterms:issued>
   <dc:type>journal article</dc:type>
   <dc:identifier>https://hdl.handle.net/20.500.14352/107692</dc:identifier>
   <dc:identifier>XXXX-XXXX</dc:identifier>
   <dc:identifier>10.3390/ph17070889</dc:identifier>
   <dc:identifier>1424-8247</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>PROYECTO PUENTE UVA 22991</dc:relation>
   <dc:relation>Lorca, M.; Muscia, G.C.; Pérez-Benavente, S.; Bautista, J.M.; Acosta, A.; González, C.; Sabadini, G.; Mella, J.; Asís, S.E.; Mellado, M. 2D/3D-QSAR Model Development Based on a Quinoline Pharmacophoric Core for the Inhibition of Plasmodium falciparum: An In Silico Approach with Experimental Validation. Pharmaceuticals 2024, 17, 889. https://doi.org/10.3390/ph17070889</dc:relation>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>open access</dc:rights>
   <dc:rights>Attribution 4.0 International</dc:rights>
   <dc:publisher>MDPI</dc:publisher>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>